Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From mAbxience S.L.
Fresenius Brings In Transparency Change For Kabi Unit
Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.
HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
Generics And Biosimilars Industry Reshaped By Transformations
The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.
Keeping Track: US FDA Novel Approvals Return With Xenpozyme, Spevigo Nods; Stimufend Survives COVID-19 Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Contract Manufacturing Organization
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- CHEMO Group
- Kevilmare Holding GmbH
- Insud Pharma
- mAbxience S.A
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.